KPV vs BPC-157
Independent, side-by-side comparison of KPV and BPC-157: mechanism, half-life, dose range, safety profile, and live vendor pricing. Updated continuously as new research and listings land.
Live price snapshot
KPV
BPC-157
KPV
KPV is a three-amino-acid peptide — Lysine-Proline-Valine — that makes up the C-terminal tail of alpha-MSH (alpha-melanocyte-stimulating hormone). With a molecular weight of only 342.4 Da, it is one of the smallest…
Live lowest price: $34.99 across 5 vendors
Full KPV profileBPC-157
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of human gastric juice…
Live lowest price: $29.00 across 15 vendors
Full BPC-157 profileSide-by-side comparison
| Attribute | KPV | BPC-157 |
|---|---|---|
| Category | Recovery | Injury, Repair & Recovery |
| Research Stage | Preclinical | Preclinical |
| Mechanism of Action | KPV's mechanism of action has been worked out in detail over the past 20 years, and it is unusual enough to be worth understanding if you are using this compound. Unlike most peptides, KPV does not primarily act through classical G-protein-coupled receptors on… | Nitric Oxide (NO) System Modulation BPC-157 exerts a central integrative effect through modulation of the nitric oxide system. Studies by Seiwerth et al. (2022) demonstrated that BPC-157 counteracts both NO-excess and NO-deficiency states, functioning as a… |
| Half-Life | ~15–30 minutes (short-lived but downstream anti-inflammatory effects persist) | Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived. |
| Typical Dose Range | 500 mcg-2 mg per dose (standard); up to 5 mg daily in advanced protocols | 200-500 mcg subcutaneous 1-2x daily (community protocols); 1-10 mcg/kg in animal studies |
| Dosing Frequency | Once daily subcutaneous or oral | Twice daily (AM and PM) for optimal serum levels; once daily acceptable |
| Administration | Subcutaneous, Oral, Topical | Subcutaneous, Oral, Intraperitoneal, Intravenous |
| Side Effects | KPV's side effect profile, based on the published literature and the research-peptide community's accumulated experience, is notable primarily for what is NOT reported. Across preclinical studies and the limited human case reports, no serious adverse events… | Generally well-tolerated. Mild nausea or GI discomfort during initial use. Temporary increase in pain/inflammation at injury site (healing response). Rare: drowsiness, dizziness, mild headache. Very rare: transient changes in blood pressure. |
| Molecular Weight | 342.43 g/mol | 1419.5 g/mol (average); molecular formula C62H98N16O22 |
| Common Vial Sizes | 5mg, 10mg | 5mg, 10mg |
Price History
4 data points- OF
- BM
- Unknown
- VANDL Labs
- Ion Peptide
Price History
7 data points- OF
- BM
- Unknown
- VANDL Labs
- Unknown
- LB
- Ion Peptide
KPV — potential benefits
- Potent anti-inflammatory effects
- Gut healing and barrier repair
- Antimicrobial properties
- Skin wound healing support
- Potential anti-cancer properties (anti-angiogenic in tumors)
BPC-157 — potential benefits
- Accelerated tendon and ligament healing with improved biomechanical strength in preclinical soft-tissue injury models (PMID: 30915550)
- Gastric and GI mucosal cytoprotection against ethanol-induced lesions, mediated in part by the nitric oxide system (PMID: 30279308)
- Healing of cysteamine-induced colitis and colon anastomosis in preclinical inflammatory bowel disease models (PMID: 24304574)
- Neuroprotection with dopaminergic and nitric oxide-system modulation in central nervous system injury models such as stroke and dopamine-receptor blockade (PMID: 34380875)
- Promotion of angiogenesis via VEGFR2 up-regulation, internalization, and VEGFR2-Akt-eNOS signaling in rat hind-limb ischemia and endothelial assays (PMID: 27847966)
- Tendon fibroblast outgrowth, cell survival, and migration through FAK-paxillin pathway activation (PMID: 21030672)
- Growth hormone receptor up-regulation in tendon fibroblasts, potentiating growth hormone's proliferative effect (PMID: 25415472)
- Nitric oxide-system interaction with endothelium protection, angiogenesis, and EGR-1-mediated growth-factor and collagen expression (PMID: 22300085)
Frequently asked
What's the difference between KPV and BPC-157?
KPV is a recovery that kpv's mechanism of action has been worked out in detail over the past 20 years, and it is unusual enough to be worth understanding if you are using this compound. unlike most…. BPC-157 is a injury, repair & recovery that nitric oxide (no) system modulation bpc-157 exerts a central integrative effect through modulation of the nitric oxide system. studies by seiwerth et al. (2022) demonstrated that…. The two differ in mechanism, half-life (~15–30 minutes (short-lived but downstream anti-inflammatory effects persist) vs Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived.), and typical dose range.
Which has the longer half-life, KPV or BPC-157?
KPV has a half-life of ~15–30 minutes (short-lived but downstream anti-inflammatory effects persist). BPC-157 has a half-life of Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived.. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, KPV or BPC-157?
Current lowest live price on BodyHackGuide: KPV from $34.99, BPC-157 from $29.00. Prices are pulled from the vendor listings tracked on BHG and change frequently — see the compare tables on each compound page for the current set of offers.
Can you stack KPV and BPC-157?
Stacking depends on mechanism overlap, safety profile, and goals. KPV and BPC-157 should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Live listings from the vendors we track, refreshed continuously.
Before you buy KPV or BPC-157
Check the vendor trust score. Every supplier we track is rated 0–100 on COA verification, payment transparency, shipping, reviews, and listings — methodology published, no pay-to-rank.
Related comparisons
Research use only. BodyHackGuide is an independent research reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. We earn an affiliate commission on some outbound clicks — this never affects the data or pricing shown. See editorial standards and affiliate disclosure.